Phase 1/2 clinical trial results demonstrate efficacy for GO-203-2C, a peptide that blocks MUC1 dimerization, in combination therapy with decitabine in acute myeloid leukemia (AML) patients [83]. This evidence concerns the gene MUC1 and acute myeloid leukemia.